BioXcel Therapeutics Announces Appointment of William P. Kane as Chief Commercial Officer Jun 16, 2020
BioXcel Therapeutics Announces First Patient Enrolled in Phase 1b/2 RELEASE Trial of BXCL501 for the Treatment of Opioid Withdrawal Symptoms Jun 11, 2020
BioXcel Therapeutics Announces Completion of Patient Enrollment in Phase 3 SERENITY Trials with BXCL501 May 14, 2020
BioXcel Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update May 12, 2020
BioXcel Therapeutics to Host First Quarter 2020 Operating and Financial Results Conference Call and Webcast May 5, 2020
BioXcel Therapeutics Announces Initiation of a Phase 2 Study of BXCL701 in Combination with a PD-1 Inhibitor for Treatment Emergent Neuroendocrine Prostate Cancer Apr 28, 2020
